a d Tamoxifen Reduces Breast Cancer Incidence by 45% in Women at High Risk of Developing the Disease | Oncolink - Cancer Resources

Tamoxifen Reduces Breast Cancer Incidence by 45% in Women at High Risk of Developing the Disease

University of Pennsylvania Cancer Center
Ultima Vez Modificado: 18 de mayo del 1998

Share article

Tamoxifen has been used for the past twenty years to treat breast cancer and prevent its recurrence. Knowledge of its benefit in preventing breast cancer remained unknown, however. Today researchers from the National Surgical Breast and Bowel Project (NSABP) presented the results of a trial examining the breast cancer prevention benefits of tamoxifen.

13,388 women participated in the placebo controlled, double-blinded randomized clinical trial. Through almost four years of follow-up, the study demonstrated that the drug reduces the incidence of breast cancer by 45% among women at high risk of the disease. "High risk" was determined by looking at each woman's family history of breast cancer, age, pregnancy history, and age at time of menstruation, among other factors.

Of those participating in the trial, 85 women on tamoxifen developed breast cancer, compared to 154 cases in the women assigned to placebo. The study did find an elevated risk of developing endometrial cancer (33 cases on tamoxifen, compared to 14 in placebo); pulmonary embolism (17 versus 6) ; and thrombosis (30 versus 19). Women under 50, however, experience no excess risk of side effects.

[ Original Abstract ]

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información